-
1
-
-
84862302379
-
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
-
May (5)
-
Yu Y., Xu X., Du Z., Shi M. Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials. Cancer Chemother Pharmacol 2012, 69(May (5)):1265-1275.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1265-1275
-
-
Yu, Y.1
Xu, X.2
Du, Z.3
Shi, M.4
-
2
-
-
84867195295
-
Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature meta-analysis
-
Xu C., Zhou Q., Wu Y. Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? A literature meta-analysis. J Hematol Oncol 2012, 5:62.
-
(2012)
J Hematol Oncol
, vol.5
, pp. 62
-
-
Xu, C.1
Zhou, Q.2
Wu, Y.3
-
3
-
-
0142055937
-
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
-
Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. J Am Med Assoc 2003, 290:2149-2158.
-
(2003)
J Am Med Assoc
, vol.290
, pp. 2149-2158
-
-
Kris, M.G.1
Natale, R.B.2
Herbst, R.S.3
Lynch, T.J.4
Prager, D.5
Belani, C.P.6
-
4
-
-
2342471392
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
-
Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
-
(2004)
N Engl J Med
, vol.350
, pp. 2129-2139
-
-
Lynch, T.J.1
Bell, D.W.2
Sordella, R.3
Gurubhagavatula, S.4
Okimoto, R.A.5
Brannigan, B.W.6
-
5
-
-
80052793410
-
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors
-
Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71:6051-6060.
-
(2011)
Cancer Res
, vol.71
, pp. 6051-6060
-
-
Sasaki, T.1
Koivunen, J.2
Ogino, A.3
Yanagita, M.4
Nikiforow, S.5
Zheng, W.6
-
6
-
-
84870297371
-
Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas
-
Dai Z., Kelly J.C., Meloni-Ehrig A., Slovak M.L., Boles D., Christacos N.C., et al. Incidence and patterns of ALK FISH abnormalities seen in a large unselected series of lung carcinomas. Mol Cytogenet 2012, 5:44.
-
(2012)
Mol Cytogenet
, vol.5
, pp. 44
-
-
Dai, Z.1
Kelly, J.C.2
Meloni-Ehrig, A.3
Slovak, M.L.4
Boles, D.5
Christacos, N.C.6
-
7
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
-
8
-
-
84868204403
-
Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma
-
May
-
Ren S., Chen X., Kuang P., Zheng L., Su C., Li J., et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012, 8(May).
-
(2012)
Cancer
, vol.8
-
-
Ren, S.1
Chen, X.2
Kuang, P.3
Zheng, L.4
Su, C.5
Li, J.6
-
9
-
-
81755161162
-
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer
-
[abstr 10517]
-
Yang J., Zhang X., Su J., Chen H., Tian H., Huang J., et al. Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. J Clin Oncol 2011, 29(Suppl.). [abstr 10517].
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Yang, J.1
Zhang, X.2
Su, J.3
Chen, H.4
Tian, H.5
Huang, J.6
-
10
-
-
84865089246
-
Analysis of receptor tyrosine kinase ROS1 positive tumors in non small cell lung cancer: identification of a FIG-ROS1 fusion
-
August (16)
-
Rimkunas V.M., Crosby E., Li Daiqiang, Hu Y., Kelly M.E., Gu T.L., et al. Analysis of receptor tyrosine kinase ROS1 positive tumors in non small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 2012, 18(August (16)):4449-4457.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 4449-4457
-
-
Rimkunas, V.M.1
Crosby, E.2
Daiqiang, L.3
Hu, Y.4
Kelly, M.E.5
Gu, T.L.6
-
11
-
-
48249114422
-
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer
-
Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 4275-4283
-
-
Koivunen, J.P.1
Mermel, C.2
Zejnullahu, K.3
Murphy, C.4
Lifshits, E.5
Holmes, A.J.6
-
12
-
-
34548849132
-
Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method
-
September
-
Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13(September):4954.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4954
-
-
Pao, W.1
Ladanyi, M.2
-
13
-
-
84875074252
-
The role of molecular pathology in non small cell lung carcinoma-now and in the future
-
June (Suppl. 1)
-
Brandao G.D.A., Brega E.F., Spatz A. The role of molecular pathology in non small cell lung carcinoma-now and in the future. Curr Oncol. 2012, 19(June (Suppl. 1)):S24-S32.
-
(2012)
Curr Oncol.
, vol.19
-
-
Brandao, G.D.A.1
Brega, E.F.2
Spatz, A.3
-
14
-
-
84874606355
-
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumor tissue and cytology samples
-
Ellison G., Zhu G., Moulis A., Dearden S., Speake G., McCormack R EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumor tissue and cytology samples. J Clin Pathol 2013, 66(2):79-89.
-
(2013)
J Clin Pathol
, vol.66
, Issue.2
, pp. 79-89
-
-
Ellison, G.1
Zhu, G.2
Moulis, A.3
Dearden, S.4
Speake, G.5
McCormack, R.6
-
15
-
-
36849065315
-
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
-
Rikova K., Guo A., Zeng Q., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
-
(2007)
Cell
, vol.131
, pp. 1190-1203
-
-
Rikova, K.1
Guo, A.2
Zeng, Q.3
Possemato, A.4
Yu, J.5
Haack, H.6
-
16
-
-
80051784751
-
Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
-
Kim H., Yoo S.B., Choe J.Y., et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol 2011, 6:1359-1366.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1359-1366
-
-
Kim, H.1
Yoo, S.B.2
Choe, J.Y.3
-
17
-
-
67650441507
-
Anaplasic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non small cell lung carcinomas
-
Boland J.M., Erdogan S., Vasmatzis G., et al. Anaplasic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non small cell lung carcinomas. Hum Pathol 2009, 40:1153-1158.
-
(2009)
Hum Pathol
, vol.40
, pp. 1153-1158
-
-
Boland, J.M.1
Erdogan, S.2
Vasmatzis, G.3
-
18
-
-
58149382583
-
A mouse model for EML4-ALK-positive lung cancer
-
Soda M., Takada S., Takeuchi K., Choi Y.L., Enomoto M., Ueno T., et al. A mouse model for EML4-ALK-positive lung cancer. Proc Natl Acad Sci USA 2008, 105:19893-19897.
-
(2008)
Proc Natl Acad Sci USA
, vol.105
, pp. 19893-19897
-
-
Soda, M.1
Takada, S.2
Takeuchi, K.3
Choi, Y.L.4
Enomoto, M.5
Ueno, T.6
-
19
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
20
-
-
80051780280
-
Initial phase II results with crizotinib in advanced ALK positive non small cell lung cancer (NSCLC): PROFILE 1005
-
2011 ASCO Annual meeting [abstr 7514]
-
Crinò L., Kim G., Riely G.J., Janne P.A., et al. Initial phase II results with crizotinib in advanced ALK positive non small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011, 29(Suppl.). 2011 ASCO Annual meeting [abstr 7514].
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL.
-
-
Crinò, L.1
Kim, G.2
Riely, G.J.3
Janne, P.A.4
-
21
-
-
78650499456
-
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation
-
December (12)
-
Kuo Y.W., Wu S.G., Ho C.C., Shih J.Y. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(December (12)):2039-2040.
-
(2010)
J Thorac Oncol
, vol.5
, pp. 2039-2040
-
-
Kuo, Y.W.1
Wu, S.G.2
Ho, C.C.3
Shih, J.Y.4
-
22
-
-
80054911665
-
Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib
-
Popat S., Vieira de Araújo A., Min T., Swansbury J., Dainton M., Wotherspoon A., et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6:1962.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 1962
-
-
Popat, S.1
Vieira de Araújo, A.2
Min, T.3
Swansbury, J.4
Dainton, M.5
Wotherspoon, A.6
-
23
-
-
78650950138
-
EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations
-
Tiseo M., Gelsomino F., Boggiani D., Bortesi B., Bartolotti M., Bozzetti C., et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71:241-243.
-
(2011)
Lung Cancer
, vol.71
, pp. 241-243
-
-
Tiseo, M.1
Gelsomino, F.2
Boggiani, D.3
Bortesi, B.4
Bartolotti, M.5
Bozzetti, C.6
-
24
-
-
84863776935
-
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation
-
Lee J.K., Kim T.M., Koh Y., Lee S.H., Kim D.W., Jeon Y.K., et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer 2012, 77:460-463.
-
(2012)
Lung Cancer
, vol.77
, pp. 460-463
-
-
Lee, J.K.1
Kim, T.M.2
Koh, Y.3
Lee, S.H.4
Kim, D.W.5
Jeon, Y.K.6
-
25
-
-
84869886632
-
A case of lung cancer adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
-
Tanaka H., Hayashi A., Morimoto T., Taima K., Tanaka Y., Shimada M., et al. A case of lung cancer adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. BMC Cancer 2012, 12:558.
-
(2012)
BMC Cancer
, vol.12
, pp. 558
-
-
Tanaka, H.1
Hayashi, A.2
Morimoto, T.3
Taima, K.4
Tanaka, Y.5
Shimada, M.6
-
26
-
-
79951773393
-
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations
-
Jianjigian Y.Y., Park B.J., Zakowoski M.F., Ladanyi M., Pao W., D'Angelo S.P., et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations. J Thorac Oncol 2011, 6:569-575.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 569-575
-
-
Jianjigian, Y.Y.1
Park, B.J.2
Zakowoski, M.F.3
Ladanyi, M.4
Pao, W.5
D'Angelo, S.P.6
|